Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04479722
Other study ID # SAFE-PROTECT
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 3, 2021
Est. completion date September 30, 2026

Study information

Verified date September 2023
Source Shanghai MicroPort Medical (Group) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of using Microport CardioAdvance Left Atrium Appendage Closure for preventing stroke in Non-valvular atrial fibrillation (NVAF) patients who have contraindications for long-term anti-coagulation. And to support registration approval from National Medical Products Administration (NMPA).


Description:

SAFE-PROTECT trial is composed of Roll-in group, small-size group and RCT group. This trial is planned to conduct in about 20 sites from China. Roll-in group plans to enroll at most 3 subjects each site to implant experimental device for exploration and observation. RCT group plans to enroll no less than 210 subjects who meet the inclusion/exclusion criteria, and 1:1 randomly allocated to experimental arm or comparator arm.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 210
Est. completion date September 30, 2026
Est. primary completion date September 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Non valvular atrial fibrillation subjects aged =18 and =80; - High risk of ischemic stroke: CHA2DS2VASc score = 2 ( = 3 for female) together with any of the following circumstances: 1. With a recorded history (happened earlier than 6 months from now) of bleeding (including gingival/nasal/oral bleeding, skin &soft tissue bleeding, gastrointestinal bleeding, urinary tract bleeding, cerebral haemorrhage, etc.) or bleeding tendency; 2. Intolerance or rejection of long-term anti-coagulation therapy; 3. Suffering stroke or embolism despite routine anti-coagulation therapy; 4. With a predicting HAS-BLED score =3. - Subjects (or his/her legal representatives) are able to understand the study objectives, willing to cooperate with procedure and follow-up. Subjects who voluntarily participate in this trial and have signed the written informed consent form. Exclusion Criteria: - Subjects with atrial fibrillation (AF) caused by rheumatic valvular disease, moderate to severe mitral stenosis, severe mitral regurgitation, severe aortic valve disease or severe left ventricular outflow tract obstruction with pressure difference greater than 40mmHg; - Suffering with other disease(s) requiring long-term oral anticoagulation treatment; - Initial untreated AF, or secondary AF with clear cause (such as hyperthyroid heart disease); - Intracardiac thrombus (including left and/or right atrium) found or persisted; - Suffered with myocardial infarction within 3 months; - History of previous atrial septum repair operation or Atrial Septal Occluder implantation; - History of previous heart valve (mechanical valve) replacement operation; - Subjects undergoing heart transplant operation; - Subjects with symptomatic carotid artery disease (such as carotid stenosis > 50%) or subjects with vulnerable carotid artery plaque. - Suffered with ischemic stroke or TIA recently (within 30 days); - Known complex active atherosclerotic plaque(s) in the descending aorta or aortic arch; - Severe heart failure (NYHA Grade ?); - The investigator assessed that there were abnormal result(s) with clinical significance in the routine blood test of subjects; - Severe renal abnormal: serum creatinine >250µmol/l; or on dialysis; - Allergic or contraindicated to aspirin, clopidogrel, heparin, contrast agent, and nitinol alloy; - Subjects who are scheduled to receive operation within 1 year after procedure, and need to stop anti-thrombotic therapy; - Pregnant or breast-feeding subjects, or subjects who plan to have a child within 1 year after procedure; - Subjects with a life expectancy less than 12 months; - Subjects who are participating in another investigational drug or device clinical trial in which the primary endpoint is still not reached before enrolment; - Subjects have other reasons that cannot maintain 2 months anticoagulation or 6 months dual antiplatelet therapy; - Subjects with poor compliance (judged by investigator) or cannot complete the study according to the protocol due to other reasons; - Subjects who are unsuitable to receive LAA occlusion treatment (judged by investigator).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Left atrial appendage closure procedure
Implant LAAC system in LAA through percutaneous intervention

Locations

Country Name City State
China Shanghai Chest Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai MicroPort Medical (Group) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical success Freedom from ischemic stroke, hemorrhagic stroke, systemic embolism, cardiovascular death and unexplained death 12-month
Secondary LAA occlusion success TEE examination showing that the residual shunt < 5mm jet width or complete occlusion of LAA 12-month
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A